In-vitro activity of trovafloxacin, a new fluoroqinolone, against recent clinical isolates

Journal of Antimicrobial Chemotherapy

Volumn 39, Issue SUPPL. B, 1997, Pages 43-49

  Felmingham, D ^a   Robbins, M J ^a   Ingley, K ^a   Mathias, I ^a   Bhogal, H ^a   Leakey, A ^a   Ridgway, G L ^b   Gruneberg R N ^b  

^a GR Micro Ltd   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; NALIDIXIC ACID; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; CHLAMYDIACEAE; CONTROLLED STUDY; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; LEGIONELLA; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MYCOPLASMA; NEISSERIA; NONHUMAN; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; UREAPLASMA UREALYTICUM;

ANTI-INFECTIVE AGENTS; CHLAMYDIA; CIPROFLOXACIN; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; MICROBIAL SENSITIVITY TESTS; MYCOPLASMA; NAPHTHYRIDINES; OFLOXACIN; UREAPLASMA;

EID: 0030790014     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/39.suppl_2.43     Document Type: Article

References (11)

1. Gooding, B. B. & Jones, R. N. (1993). In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrobial Agents and Chemotherapy 37, 349-53.
2. Felmingham, D. (1992). New fluoroquinolone antimicrobials - the Gram-positive challenge! Reviews in Medical Microbiology 3, 175-85.
3. National Committee for Clinical Laboratory Standards. (1993). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Third Edition; Approved Standard. NCCLS document M7-A3. NCCLS, Wayne, PA.
4. National Committee for Clinical Laboratory Standards. (1993). Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria - Third Edition; Approved Standard. NCCLS Document M11A3. NCCLS, Wayne, PA.
5. Ridgway, G. L., Mumtaz, G., Gabriel, F. G. & Oriel, J. D. (1984). The activity of ciprofloxacin and other 4-quinolones against Chlamydia trachomatis and mycoplasmas in vitro. European Journal of Clinical Microbiology 3, 344-6.
6. Eliopoulos, G. M., Klimm, K., Eliopoulos, C. T., Ferraro, M. J. & Moellering, R. C. (1993). In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of Gram-positive bacteria. Antimicrobial Agents and Chemotherapy 37, 366-70.
7. Gootz, T. D., Brightly, K. E., Anderson, M. R., Schmieder, B. J., Haskell, S. L., Sutcliffe, J. A. et al. (1994). In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl)naphthyridone antimicrobial. Diagnostic Microbiology and Infectious Disease 19, 235-43.
8. Child, J., Andrews, J., Boswell, F., Breuwald, N. & Wise, R. (1995). The in-vitro activity of CP 99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. Journal of Antimicrobial Chemotherapy 35, 869-76.
9. Spangler, S. K., Jacobs, M. R. & Appelbaum, P. C. (1994). Activity of CP-99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrobial Agents and Chemotherapy 38, 2472-6.
10. Teng, R., Harris, S. C., Nix, D. E., Schentag, J. J., Foulds, G. & Liston, T. E. (1995). Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. Journal of Antimicrobial Chemotherapy 36, 385-94.
11. Mann, H. J., Bitterman, P. B., Anderson, A. C., Teng, R., Johnson, A., Avery, M. et al. (1995). CP-99,219 penetration into human bronchial tissues and fluids following the administration of a single dose. In Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995. Abstract F241, p. 155. American Society for Microbiology, Washington, DC.